The account argues the two get lumped together as peptides but rest on very different research, and urges asking who was studied and for how long.
Recap by typeshit. Post by @longevity.technology on Instagram.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
Lilly Medical points to newly published results from a double-blind, placebo-controlled phase 3 study of its triple-hormone shot in people with diabetes.
Topol points to work suggesting the body's own GLP-1 family peptides help reduce inflammation in the gut. Details are thin, so tap through for the study.
Medscape explores whether GLP-1 medicines might help keep people with schizophrenia out of the hospital. Tap through for the evidence behind the idea.
BoxLife recaps the ranking: retatrutide gets B, BPC-157 low C, NAD+ D and epitalon F. Exercise is the only thing Nippard puts in S tier.
The Leslie Dan Faculty of Pharmacy group will build a database and train an AI model to help identify peptides with therapeutic potential.
Loading…